A large McGill University study has found that two classes of medications commonly prescribed for Type 2 diabetes, both incretin-based, are associated with a reduced risk of dementia.
Drawing on clinical data from more than 450,000 patients, the research adds to growing evidence that incretin-based therapies have protective benefits for the brain.
The study examined GLP-1 receptor agonists, which include such medications as Ozempic, as well as DPP-4 inhibitors.
The Social Science and Humanities Research Council of Canada (SSHRC) announced recipients of the latest Partnership Engage Grants competition, including a total of $73,782 awarded to three McGill researchers.
Thursday March 12 2026 • 4:30pm to 6pm
Dentistry Suite #102, 2001 Avenue McGill College
Anna Papafragou, PhD
Professor • Department of Linguistics, University of Pennsylvania
A McGill-led study is challenging a popular theory about how dopamine drives movement, a discovery that could shift how scientists think about Parkinson’s disease treatments.
Published in Nature Neuroscience, the research found dopamine does not set the speed or force of each movement, as had been thought. Instead, it appears to act as the underlying support system that makes movement possible.
A new study has linked air pollution exposure and immune-system changes that often precede the onset of autoimmune diseases.
McGill University researchers analyzing Ontario data found that fine particles in air pollution are associated with higher levels of a biomarker linked with autoimmune diseases, such as systemic lupus.
On Saturday, November 8, 2025, Healthy Brains, Healthy Lives (HBHL) presented the third edition of the Amazing Brain Science Talks, in partnership with Brain Canada Foundation and the Brain-Heart Interconnectome. Held at the Grande Bibliothèque in Montreal, the event attracted over 100 attendees for an engaging afternoon discussing popular topics in brain health.
The University continues to be recognized as one of Canada’s top research institutions and drivers of innovation
A program developed by a McGill researcher to help cancer survivors cope with the fear their cancer will return is expanding across Canada.
The Fear of Recurrence Therapy (FORT) program offers evidence-based support to address what co-founder Christine Maheu calls one of the most overlooked aspects of recovery.
Sam Harper and Arijit Nandi have received funding to help strengthen national capacity in metaresearch through the Research-on-Research joint initiative, supported by the Social Sciences and Humanities Research Council (SSHRC), the Canadian Institutes of Health Research (CIHR), and Michael Smith Health Research BC (MSHRBC).
Twenty-four McGill researchers have been named to the 2025 Highly Cited Researchers™ list, a ranking prepared each year by Clarivate, an analytics company based in the US. The list assesses researchers in a wide range of disciplines, from neuroscience to environmental science. The number of McGill scholars on the list grew from 14 in 2024 to 24 in 2025.
A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer.
McGill University researchers at the Rosalind and Morris Goodman Cancer Institute (GCI) identified a mechanism driving neuroendocrine prostate cancer, a rare and highly aggressive subtype for which there currently are no effective treatment options.
McGill University researchers at the Douglas Research Centre have found evidence that heavy cannabis use during pregnancy can cause delays in brain development in the fetus that persist into adulthood.
Using advanced MRI techniques, the team tracked the effects of prenatal cannabis exposure in mice across key developmental stages.
A diagnosis often viewed as less serious than anorexia and bulimia – and the most common eating disorder worldwide – can cause just as much harm, a new study has found.
No appointment needed.
First come, first serve.
Thank you
